$10.17
0[0.00%]
At close: Apr 25
$10.17
0[0.00%]
PreMarket: 4:20PM EDT
Amicus Therapeutics
(NASDAQ:FOLD)Latest News for Amicus Therapeutics Stock (NASDAQ:FOLD)
Amicus Therapeutics Stock (NASDAQ: FOLD)
Categories: All
Monday, March 18, 2024
Thursday, February 29, 2024
Wednesday, February 28, 2024
- Amicus Therapeutics Projects 2024 Galafold Revenue Growth Of 11-16% At CER, Anticipates Full-Year Non-GAAP Profitability In 2024Benzinga Newsdesk - Feb 28, 2024, 7:07AM
- Amicus Therapeutics Q4 Adj EPS $0.01 Beats $(0.06) Estimate, Sales $115.08M Beat $114.33M EstimateBenzinga Newsdesk - Feb 28, 2024, 7:06AM
- Earnings Scheduled For February 28, 2024Benzinga Insights - Feb 28, 2024, 6:24AM
Thursday, February 08, 2024
Tuesday, December 19, 2023
Tuesday, December 05, 2023
Thursday, November 09, 2023
Wednesday, November 08, 2023
- Amicus Therapeutics Is On-Track To Achieve Non-GAAP Profitability In Q4 2023Benzinga Newsdesk - Nov 8, 2023, 7:13AM
- For FY23, Amicus Therapeutics Is Increasing Galafold Revenue Growth Guidance To Between 16 And 18% At CERBenzinga Newsdesk - Nov 8, 2023, 7:11AM
- Amicus Therapeutics Q3 EPS $(0.07) Beats $(0.08) Estimate, Sales $103.50M Beat $101.36M EstimateBenzinga Newsdesk - Nov 8, 2023, 7:10AM
- Earnings Scheduled For November 8, 2023Benzinga Insights - Nov 8, 2023, 4:21AM
Tuesday, October 10, 2023
Monday, October 02, 2023
Friday, September 29, 2023
Thursday, September 28, 2023
- Amicus Therapeutics Drug Scores FDA Approval For Rare Inherited Pompe DiseaseVandana Singh - Sep 28, 2023, 12:41PM
- Amicus Therapeutics Shares Resume TradeBenzinga Newsdesk - Sep 28, 2023, 11:10AM
- Amicus Therapeutics, Inc. Shares To Resume Trade At 11:10 a.m. ETBenzinga Newsdesk - Sep 28, 2023, 10:52AM
- Amicus Therapeutics Announces FDA Approval And Launch Of New Treatment For Pompe DiseaseBenzinga Newsdesk - Sep 28, 2023, 10:43AM
- Amicus Therapeutics Shares Halted, News PendingBenzinga Newsdesk - Sep 28, 2023, 8:29AM
Monday, August 21, 2023
Tuesday, August 15, 2023
Tuesday, August 08, 2023
- Amicus Therapeutics shares are trading higher following a Q2 revenue beat.Bill Haddad - Aug 8, 2023, 1:05PM
- Amicus Therapeutics Q2 EPS $(0.15) Misses $(0.12) Estimate, Sales $94.50M Beat $89.87M EstimateBenzinga Newsdesk - Aug 8, 2023, 7:05AM
- Earnings Scheduled For August 8, 2023Benzinga Insights - Aug 8, 2023, 4:48AM
Tuesday, July 11, 2023
Monday, June 26, 2023
Wednesday, May 10, 2023
- Fabry Disease Treatment Showdown: Protalix Bio's Elfabrio Joins the Ranks of Sanofi and Amicus TherapeuticsVandana Singh - May 10, 2023, 2:16PM
- Earnings Scheduled For May 10, 2023Benzinga Insights - May 10, 2023, 9:12AM
- Amicus Therapeutics Expects FY23 Galafold Revenue Growth Of 12%-17% at CER; On-Track For Adj Profitability In 2H of 2023Benzinga Newsdesk - May 10, 2023, 7:25AM
- Amicus Therapeutics: Q1 Earnings InsightsBenzinga Insights - May 10, 2023, 7:15AM
- Amicus Therapeutics Q1 EPS $(0.18) Misses $(0.15) Estimate, Sales $86.27M Beat $83.08M EstimateBenzinga Newsdesk - May 10, 2023, 7:01AM